Yasmir J Quiroz-Perozo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasmir J Quiroz-Perozo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Vivas
Instituto Venezolano de Investigaciones Científicas (IVIC)
1 shared publication - Arlene Cardozo-Urdaneta
Instituto Venezolano de Investigaciones Científicas (IVIC), Centro de Biomedicina Molecular (CBM) - Dr. Humberto Fernández–Morán, Venezuela
1 shared publication - Felix Martinez-Rios
Universidad Panamericana
1 shared publication - Jhoan Toro-Mendoza
Instituto Venezolano de Investigaciones Cientificas, Venezuela
1 shared publication - Joan Vera-Villalobos
Escuela Superior Politécnica del Litoral
1 shared publication - Jose Luis Paz
Departamento Académico de Química Inorgánica, Facultad de Química e Ingeniería Química, Universidad Nacional Mayor de San Marcos, Lima 15081, Peru
1 shared publication
Latest Publications
- Open Access
- 26 March 2025
- Published by MDPI AG in Preprints.org
Conformational Changes in Nf-κB Induced by Interaction with Sildenafil: A Biophysical-Computational Approach with Implications for Inflammatory Diseases
Background: Hypertension and Chronic Kidney Disease (CKD) are interconnected conditions, with the activation of the transcription factor NF-κB playing a crucial role. Sildenafil used for erectile dysfunction and pulmonary hypertension, may exhibit anti-inflammatory effects by interacting and modulating the structure of NF-κB. Methods: We employed various computational techniques to explore the interaction between sildenafil and NF-κB, including molecular docking, molecular dynamics (MD) simulations, elastic network models, statistical potentials, and volumetric analyses of internal cavities. Results: Sildenafil induces conformational changes in NF-κB, potentially reducing its activity. Molecular docking showed sildenafil’s inhibitory potency is comparable to known anti-inflammatory compounds like resveratrol. MD simulations indicated that sildenafil destabilizes NF-κB’s structure, which may impact its biological function. Experimental validation was conducted using biopsies from hypertensive and kidney-damaged rat models, treated and untreated with sildenafil. Histological and immunoperoxidase analyses assessed cellular infiltration, kidney damage, and NF-κB expression, demonstrated that sildenafil treatment significantly reduced cellular infiltration, kidney damage, and NF-κB expression, confirming its anti-inflammatory properties. Conclusion: sildenafil’s potential to modulate NF-κB activity, offering a promising therapeutic strategy for managing hypertension and CKD. These preliminary findings suggest that sildenafil could be repurposed to provide comprehensive treatment for these conditions, leveraging its molecular and biochemical interactions with NF-κB.
- 26 March 2025
- Published by MDPI AG in Preprints.org
Open AccessConformational Changes in Nf-κB Induced by Interaction with Sildenafil: A Biophysical-Computational Approach with Implications for Inflammatory Diseases
Background: Hypertension and Chronic Kidney Disease (CKD) are interconnected conditions, with the activation of the transcription factor NF-κB playing a crucial role. Sildenafil used for erectile dysfunction and pulmonary hypertension, may exhibit anti-inflammatory effects by interacting and modulating the structure of NF-κB. Methods: We employed various computational techniques to explore the interaction between sildenafil and NF-κB, including molecular docking, molecular dynamics (MD) simulations, elastic network models, statistical potentials, and volumetric analyses of internal cavities. Results: Sildenafil induces conformational changes in NF-κB, potentially reducing its activity. Molecular docking showed sildenafil’s inhibitory potency is comparable to known anti-inflammatory compounds like resveratrol. MD simulations indicated that sildenafil destabilizes NF-κB’s structure, which may impact its biological function. Experimental validation was conducted using biopsies from hypertensive and kidney-damaged rat models, treated and untreated with sildenafil. Histological and immunoperoxidase analyses assessed cellular infiltration, kidney damage, and NF-κB expression, demonstrated that sildenafil treatment significantly reduced cellular infiltration, kidney damage, and NF-κB expression, confirming its anti-inflammatory properties. Conclusion: sildenafil’s potential to modulate NF-κB activity, offering a promising therapeutic strategy for managing hypertension and CKD. These preliminary findings suggest that sildenafil could be repurposed to provide comprehensive treatment for these conditions, leveraging its molecular and biochemical interactions with NF-κB.